New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference held on April 15-16, 1996, in by N. BazanNew Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference held on April 15-16, 1996, in by N. Bazan

New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference…

byN. BazanEditorJack H. Botting, Sir John R. Vane

Paperback | October 16, 2012

Pricing and Purchase Info

$173.23 online 
$191.95 list price save 9%
Earn 866 plum® points

Prices and offers may vary in store

Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

This volume contains the proceedings of the William Harvey Research Conference held in New Orleans on the 15th and 16th of April 1996. It reviews the general pathophysiological significance of the isoforms of cyclooxygenase and the likely value of selective COX-2 inhibitors in the treatment of rheumatoid conditions. The volume also covers the possible use of antibodies against cytokines and cell adhesion receptors in the treatment of inflammatory conditions.
Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College...
Loading
Title:New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules Proceedings of a conference…Format:PaperbackDimensions:147 pages, 23.5 × 15.5 × 0.17 inPublished:October 16, 2012Publisher:Springer-Verlag/Sci-Tech/TradeLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:940106265X

ISBN - 13:9789401062657

Look for similar items by category:

Reviews

Table of Contents

Preface. 1. The History of Anti-Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2synthase-1 (COX-1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase-2; S.H. Ferreira. 5. Brain COX-2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase-2 Inhibitors; A.W. Ford-Hutchinson. 7. Characteristics of Cyclooxygenase-1 and Cyclooxygenase-2-Deficient Mice; S.G. Morham, R. Langenbach. 8. X-Ray Crystal Structure of Human Cyclooxygenase-2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non-Steroid Anti-Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase-2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX-1/COX-2 Inhibition by Non-Steroid Anti-Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX-2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase-2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.